Abstract
INTRODUCTION
In developing countries, traditional medicine is still used in the primary treatment of many diseases, although few of these remedies have been reported scientifically in the literature. In response to the accelerating rate of cancer, osteoarthritis (OA) and obesity worldwide, the study of anti-inflammatory and anticancer crude medicinal plant extracts has gained considerable attention, perhaps because the current available treatment methods for these defects are expensive, have devastating side effects or are incapable of restoring all the normal biomechanical characteristics completely in damaged human tissues and organs [1] [2] [3] .
The worldwide alarming prevalence of OA, arthritis, osteoporosis, atherosclerosis and rheumatoid arthritis, with few, if any, current effective treatment measures, cannot be overlooked. In Canada, 4.5 million people older than 15 years have arthritis and it is estimated that 7 million people will have arthritis by 2031 [4] . It has been estimated that 27 million Americans will suffer from OA by 2020. Studies have shown that joint disease will be at increase in South African because 70 % of their women are overweight or obese. This paves way for an upsurge of joint diseases if no health measures are taken [5] .
A cell-based approach to using stem cells and herbal solutions for stimulation, protection and anti-inflammatory purposes in the regeneration and repair of bone, tissues, organs and cartilage in transplantation is promising both in tissue engineering and for therapeutic uses [6] .
According to a World Health Organization (WHO) report, 80 % of people in Africa (South Africa) depend upon herbal drugs for their therapeutic effectiveness [7] , yet little is known about medicinal plants, their extracts and morphogenetic factors.
Indigenous medicinal plants have been used traditionally as a major source of drugs for the treatment of various illnesses, including OA, asthma, cancer, heart disease, tuberculosis, swollen ankles and hypertension [8, 14, 45] . Extracted compounds of medicinal plants are usually employed as inputs in toxicology, phytochemicals, pharmaceuticals and other chemical industries [7, 8, 14] Knowledge of the above-mentioned properties of E. autumnalis will help in addressing and clarifying its use in the production of drugs and for other therapeutic purposes, especially in the treatment of inflammatory diseases and cancer. E. autumnalis plant species are extensively used E. autumnalis is divided into three subspecies and can be identified by the structure of the stalk of the inflorescence (peduncle) and geographical location, but generally the peduncle is either club-shaped or cylindrical. The subclasses of E autumnalis are E. autumnalis amaryllidifolia, E. autumnalis autumnalis (undulata) and E. autumnalis clavata (Figure 1 ). two dibenzo-α-pyrones (structure corresponding to xanthones), two spirocyclic nortriterpenoids (structure of these compounds confirmed by the x-ray structure of pbromobenzene sulphate derivative) and an acid compound have been isolated (Table 3) . Moreover, E. autumnalis leaves, bulbs and roots are known to inhibit the synthesis of prostaglandin, thereby protecting the cyclooxygenase enzymes COX-1 and COX-2 [12,16,24,25].
Anti-inflammatory properties
The most popular traditional use of E. autumnalis species has been for anti-inflammatory and fracture purposes (Table 1) , hence they are recommended to be used in the manufacturing of non-steroidal anti-inflammatory drugs (NSAID). The anti-inflammatory capacity of E. autumnalis varies according to the part of the plant [26,27,12,16].
Generally, anti-inflammatory activity in the E. autumnalis plant depends on age, season, fertilization and growth conditions [17, 18, 24, 25] .
During inflammation, prostaglandins are involved and are responsible for the sensation of pain. Numerous studies have investigated the antiinflammatory effects of E. autumnalis by evaluating the efficacy of its extracts for prostaglandin synthesis. This in vitro assay tends to measure the degree of inhibition of Cyclooxygenase enzyme activity. Cyclooxygenase exists in two isoforms, COX-1 Over-exploitation is another environmental factor that can affect E. autumnalis subspecies. A study by [28] showed that the mean size of the bulbs decreased significantly between 1995 and 2001. This was believed to be an indication of overexploitation. Another study also confirmed its decline as a result of over-exploitation [29] .
Possible role of Eucomis autumnalis in osteoarthritis defects
OA is the best known form of arthritis, a chronic inflammatory progressive disorder of the joints, characterized by late onset degeneration of articular cartilage. Degeneration of articular cartilage is marked by the breakdown of cartilage matrix proteins. OA causes pain, synovial inflammation, joint deterioration and subchondral bone alteration [39, 40] . It usually affects aged people but it can also affect young individuals [40] [41] [42] .
OA is characterized by relatively few cells with low cell mobility owing to the neighboring matrix and a limited number of progenitor cells [43, 44] . These factors retard cartilage regeneration and repair; as a result symptoms associated with OA occur [45] . The methods currently used to treat OA, such as NSAIDS and autologous chondrocyte implantation (ACI), mainly revolve around, i) pain management, ii) rehabilitation and iii) surgery to treat loss of joint function, with negative side effects. Furthermore, there are problems associated with donor site morbidity, difficulty in harvesting a large number of chondrocytes without causing substantial additional damage and the very high cost of treatment [46] [47] [48] . A positive outcome has been reported for ACI, involving chondrocyte isolation from the cartilage, in vitro expansion and reimplantation into the cartilage defect by a periosteal graft [49, 50] . The main disadvantages of ACI is the requirement for an invasive surgical procedure and the fact that chondrocytes that are expanded in culture gradually undergo differentiation and lose morphological features and specialized functions [51, 52] .
However, treatment of OA joints with a wide range of growth factors necessary for maintenance of cartilage homeostasis in vitro and in vivo remain a challenge. One alternative or rather a combination approach to the standard treatment methods will be to test traditional medicinal plants that are likely to stop the progress of OA or at least slow it down to a satisfactory degree. The drug of choice for treating OA should be one that has antiinflammatory properties with no side effects. The genus E. autumnalis has been found to have anti-inflammatory, anti-bacterial, antitumor/cancer, anti-oxidative and anti-histaminic characteristics [8, [16] [17] [18] [19] .
Preliminary results from our study on articular cartilage chondrocytes showed that E. autumnalis is fastacting, with maximum cell viability and proliferation noticed within the first 24-48 hours of incubation. The anti-inflammatory property of E. autumnalis indicates its potential to exert a chondroprotective effect. Future studies on this plant must focus on exploring the potential effects of E. autumnalis plant extracts on stem cells. The experimental procedure must focus on influencing stem cells' transduction pathways; this is crucial for the induction of cell differentiation, improving proliferative capacity, expressing articular cartilage anabolic markers and inhibiting cartilage mineralization.
Eucomis autumnalis in bone regeneration
Bone healing after fracture has been described in four phases. The first phase is the inflammatory phase characterized by hematoma formation and the release of pro-inflammatory cytokines from the surrounding cells. This is followed by the soft callus phase, where chondrocytes begin to form cartilage tissue that creates a bridge at the fracture gap. The next phase is the hard callus phase, where the fragile cartilage is transformed into woven bone, through the deposition of calcium and phosphate into the cartilage [53] . Finally, the bone remodeling phase takes place where bone is restored to its previous form and function. Clinical conditions such as rheumatoid arthritis, osteoporosis, diabetes mellitus, or ageing have been reported to increase the time it takes for a fracture to heal and the possibility of complications such as fracture non-union [54] .
E. autumnalis has been found to have antiinflammatory activity and inhibition of prostaglandin synthesis was investigated by assessing the inhibition of the cyclooxygenase enzymes COX-1 and COX-2 [12, 16 33]. E. autumnalis ethanol extract has shown up to 80 % COX-1 inhibition, while the water extract showed 60 % COX-1 inhibition [33] . Gesternfeld and colleagues [55] [56] [57] studied the effect of COX inhibitors on fracture healing and reported that COX-2 inhibitors delayed fracture healing while COX-1 inhibitors showed no negative effects on bone healing. Other studies have shown that different medicinal plants, which also have antiinflammatory effects similar to those of E. autumnalis, can stimulate osteoblast function, and inhibit osteoclast and adipocyte functions either alone or in combination [58] [59] [60] .
Similarly, E. autumnalis extract may stimulate bone formation by virtue of its anti-inflammatory properties (Figure 2 ). Cytokines, chemokines and prostaglandins have been identified as regulators of immuneinflammatory process in bone and cartilage formation. Cytokines like interleukin-1 and tumor necrosis factor-α are well known factors that can induce bone resorption indirectly in host cells by promoting the differentiation and activation of osteoclast precursors [61, 62] . Since E. autumnalis has anti-inflammatory property, it can be employed just like non-steroid antiinflammatory drugs in host modulatory therapy during intervention for nonsurgical therapy, in other to restore balance between proinflammatory mediators, as anti-inflammatory mediator and enzyme inhibitors [Fig 2] . Furthermore, E. autumnalis may help reduce the significant unwanted effects of nonsteroidal anti-inflammatory drugs such as hemorrhage, gastrointestinal problems and rebound effects in patients [63, 64] . The E. autumnalis extract may provide a safe and cost-effective alternative treatment for bone fracture and complications such as non-union. Despite the popular use of this medicinal plant for rapid fracture healing, there are currently no reported studies investigating the effect of this plant extract on bone repair and regeneration.
CONCLUSION
Generally, with the extensive screening of plants used in traditional medicine, evidence of their rational use in treating infections, diseases, inflammation and other disorders has been provided. Despite the huge potential of these herbal plants, a definite gap exists in research on them -little information is available on indigenous South African plants like E. autumnalis.
In nature, E. autumnalis subspecies have a widespread distribution, extending across all of the provinces of South Africa, as well as neighboring countries. A few isolated compounds have been recorded in the literature on these subspecies and the variations in the phytochemical properties of the isolated compounds are yet to be investigated. The review highlighted some environmental factors capable of affecting the availability of E. autumnalis species. The effects of these environmental contaminants should always be considered when reporting on biological activities of crude plant extracts. E. autumnalis as a medicinal plant has a highly potential role in bone formation and cartilage regeneration. Its possible role in bone and tissue regeneration is an important factor in OA, obesity, osteoporosis therapeutics and other inflammatory diseases. Further studies should be undertaken highlighting more on E autumnalis properties that enhances its performance in regenerative medicine. 
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